GM1 Oligosaccharide Efficacy in Parkinson's Disease: Protection against MPTP.
Ontology highlight
ABSTRACT: Past evidence has shown that the exogenous administration of GM1 ganglioside slowed neuronal death in preclinical models of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons: however, the physical and chemical properties of GM1 (i.e., amphiphilicity) limited its clinical application, as the crossing of the blood-brain barrier is denied. Recently, we demonstrated that the GM1 oligosaccharide head group (GM1-OS) is the GM1 bioactive portion that, interacting with the TrkA-NGF complex at the membrane surface, promotes the activation of a multivariate network of intracellular events regulating neuronal differentiation, protection, and reparation. Here, we evaluated the GM1-OS neuroprotective potential against the Parkinson's d
SUBMITTER: Fazzari M
PROVIDER: S-EPMC10216367 | biostudies-literature | 2023 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA